2019
DOI: 10.1024/0301-1526/a000787
|View full text |Cite
|
Sign up to set email alerts
|

Cell therapy of critical limb ischemia-problems and prospects

Abstract: Summary. Cell therapy is proposed for indirect revascularization for the patient’s incurable by endovascular or surgical revascularization. The therapy with stem cells (SCs) or progenitor cells is assumed to be more efficient as compared with protein or gene therapy not only because of their direct vasculogenic properties, but also thanks to their paracrine effect via secretion of manifold biologically active substances. This review gives an overview of the potential of SC-based therapy for critical limb ische… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(9 citation statements)
references
References 77 publications
0
7
0
Order By: Relevance
“…Currently, multiple growth factors and stem cells have been tried as an angiogenic promoter [ [5] , [6] , [7] ]. However, their clinical applications are limited due to their short half-life, poor stability, off-target effects, high cost and overlook the harmful microenvironment of ischemic tissue [ 8 , 9 ]. The overexpressed H 2 O 2 in ischemic muscles results in inflammatory responses and disturbs the promotion of angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) expression [ 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Currently, multiple growth factors and stem cells have been tried as an angiogenic promoter [ [5] , [6] , [7] ]. However, their clinical applications are limited due to their short half-life, poor stability, off-target effects, high cost and overlook the harmful microenvironment of ischemic tissue [ 8 , 9 ]. The overexpressed H 2 O 2 in ischemic muscles results in inflammatory responses and disturbs the promotion of angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) expression [ 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, cell transplantation-based therapy using stem or progenitor cells from different sources into ischemic tissues emerged as a new approach to stimulate angiogenesis and/or vasculogenesis. Among the different cell populations used, endothelial progenitor cells (EPCs), mesenchymal stromal cells (MSCs), and bone marrowmononuclear cells demonstrated their benefit in preclinical studies for ischemic disease treatment [10][11][12].…”
Section: Introductionmentioning
confidence: 99%
“…The adaptive vascular responses of arteriogenesis and angiogenesis are compromised within the ischaemic muscle of many CLI patients and this insufficiency in microvascular remodelling is a major predictor of disease prognosis . Therapeutic strategies to stimulate microvascular remodelling also have achieved limited success, despite promising results in pre‐clinical models . Patients with CLI experience chronic ischaemic myopathy, including myofibre atrophy and dysfunction, as well as an excessive accumulation of fatty and/or fibrotic tissue, indicating sustained deficits in muscle regeneration.…”
Section: Introductionmentioning
confidence: 99%